Breast and/or ovarian cancer: genes and variants
Explore variant evidence for Breast and/or ovarian cancer across 12 analyzed proteins (TP53, CHEK2, RAD51D, PMS2, BARD1 and 7 more). Linked ClinVar records include 5 pathogenic or likely pathogenic variants, 73 variants of uncertain significance and 101 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-04. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Breast and/or ovarian cancer
TP53: Cellular tumor antigen p53
It coordinates transcriptional responses to DNA damage and other cellular stresses, promoting cell-cycle arrest, senescence, DNA repair, or apoptosis when appropriate. Loss of this tumor-suppressive control is one of the most common events in cancer, while germline pathogenic variants cause Li-Fraumeni syndrome.
3 ClinVar pathogenic / likely pathogenic and 8 uncertain variants in TP53 have source records linked to Breast and/or ovarian cancer. Association strength is not clinical gene validity.
CHEK2: Serine/threonine-protein kinase Chk2
It propagates DNA-damage checkpoint signals to proteins controlling cell-cycle arrest, repair, and apoptosis. Germline loss-of-function variants confer moderate cancer susceptibility, especially for breast cancer, while risk estimates depend on the specific allele and family context.
1 ClinVar pathogenic / likely pathogenic and 25 uncertain variants in CHEK2 have source records linked to Breast and/or ovarian cancer. Association strength is not clinical gene validity.
RAD51D: DNA repair protein RAD51 homolog 4
It supports RAD51-mediated homologous recombination and chromosome stability after DNA double-strand breaks. Heterozygous loss-of-function variants confer substantial ovarian-cancer risk and a more moderate increase in breast-cancer susceptibility.
1 ClinVar pathogenic / likely pathogenic and 15 uncertain variants in RAD51D have source records linked to Breast and/or ovarian cancer. Association strength is not clinical gene validity.
PMS2: Mismatch repair endonuclease PMS2
Together with MLH1, it provides endonuclease activity needed to complete DNA mismatch repair after replication errors are recognized. Germline loss-of-function variants cause Lynch syndrome, while biallelic variants cause constitutional mismatch-repair deficiency.
0 ClinVar pathogenic / likely pathogenic and 31 uncertain variants in PMS2 have source records linked to Breast and/or ovarian cancer. Association strength is not clinical gene validity.
BARD1: BRCA1-associated RING domain protein 1
It forms a heterodimer with BRCA1 that supports homologous recombination, DNA-damage signaling, and ubiquitin-dependent regulation at damaged chromatin. Germline loss-of-function variants confer increased breast-cancer susceptibility, particularly for some aggressive subtypes.
0 ClinVar pathogenic / likely pathogenic and 16 uncertain variants in BARD1 have source records linked to Breast and/or ovarian cancer. Association strength is not clinical gene validity.
MLH1: DNA mismatch repair protein Mlh1
The protein partners with PMS2 to form MutL alpha, a core complex in post-replicative DNA mismatch repair. By helping correct copying errors in DNA, MLH1 protects genome stability, and inherited MLH1 variants are a major cause of Lynch syndrome.
0 ClinVar pathogenic / likely pathogenic and 14 uncertain variants in MLH1 have source records linked to Breast and/or ovarian cancer. Association strength is not clinical gene validity.
STK11: Serine/threonine-protein kinase STK11
It activates AMPK-family kinases to coordinate cellular energy sensing, polarity, and growth restraint. Germline loss-of-function variants cause Peutz-Jeghers syndrome and its associated cancer predisposition, while somatic loss is common in lung and other cancers.
0 ClinVar pathogenic / likely pathogenic and 14 uncertain variants in STK11 have source records linked to Breast and/or ovarian cancer. Association strength is not clinical gene validity.
RAD51C: DNA repair protein RAD51 homolog 3
It participates in RAD51-paralog complexes that promote homologous-recombination repair and restart damaged replication forks. Heterozygous loss-of-function variants increase ovarian and breast-cancer risk, while biallelic variants can cause Fanconi anemia.
0 ClinVar pathogenic / likely pathogenic and 11 uncertain variants in RAD51C have source records linked to Breast and/or ovarian cancer. Association strength is not clinical gene validity.
CDH1: Cadherin-1
Its E-cadherin-mediated adhesion preserves epithelial architecture and suppresses inappropriate cell detachment and invasion. Germline loss-of-function variants cause hereditary diffuse gastric cancer syndrome and substantially increase diffuse gastric and lobular breast-cancer risk.
0 ClinVar pathogenic / likely pathogenic and 10 uncertain variants in CDH1 have source records linked to Breast and/or ovarian cancer. Association strength is not clinical gene validity.
BRIP1: Fanconi anemia group J protein
It unwinds DNA structures and works with BRCA1 and the Fanconi-anemia pathway to repair damaged replication intermediates and interstrand crosslinks. Biallelic loss causes Fanconi anemia group J, while heterozygous loss-of-function variants increase ovarian-cancer risk.
0 ClinVar pathogenic / likely pathogenic and 9 uncertain variants in BRIP1 have source records linked to Breast and/or ovarian cancer. Association strength is not clinical gene validity.
MSH2: DNA mismatch repair protein Msh2
The protein forms mismatch-recognition complexes with MSH6 or MSH3 that detect base mismatches and insertion-deletion loops in DNA. This first step of mismatch repair helps preserve genome integrity, and inherited MSH2 variants are associated with Lynch syndrome.
0 ClinVar pathogenic / likely pathogenic and 7 uncertain variants in MSH2 have source records linked to Breast and/or ovarian cancer. Association strength is not clinical gene validity.
MSH6: DNA mismatch repair protein Msh6
Together with MSH2, it recognizes single-base mismatches and small insertion-deletion loops during DNA replication and initiates mismatch repair. Germline loss-of-function variants cause Lynch syndrome, while biallelic variants can cause constitutional mismatch-repair deficiency.
0 ClinVar pathogenic / likely pathogenic and 6 uncertain variants in MSH6 have source records linked to Breast and/or ovarian cancer. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): PALB2, ATM and PTEN.
ClinVar pathogenic and likely pathogenic variants linked to Breast and/or ovarian cancer
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| CHEK2 R145W | 145 | FHA | Pathogenic / likely pathogenic (★★) |
| RAD51D S207L | 207 | Pathogenic / likely pathogenic (★★) | |
| TP53 R158H | 158 | DNA binding | Pathogenic / likely pathogenic (★★) |
| TP53 R213Q | 213 | DNA binding | Pathogenic / likely pathogenic (★★) |
| TP53 R267W | 267 | DNA binding | Pathogenic / likely pathogenic (★★) |
Same protein, different disease
- Li-Fraumeni syndrome also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Breast and/or ovarian cancer variants (188 pathogenic / likely pathogenic).
- Adrenocortical carcinoma, hereditary also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Breast and/or ovarian cancer variants (23 pathogenic / likely pathogenic).
- Acute myeloid leukemia also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Breast and/or ovarian cancer variants (6 pathogenic / likely pathogenic).
- Hereditary breast ovarian cancer syndrome also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Breast and/or ovarian cancer variants (6 pathogenic / likely pathogenic).
- Hereditary breast cancer also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Breast and/or ovarian cancer variants (5 pathogenic / likely pathogenic).
- CHEK2-related cancer predisposition also has ClinVar records linked to CHEK2 variants; they fall mostly in different places as the Breast and/or ovarian cancer variants (3 pathogenic / likely pathogenic).
- Hereditary breast cancer also has ClinVar records linked to CHEK2 variants; they fall mostly in different places as the Breast and/or ovarian cancer variants (3 pathogenic / likely pathogenic).
Diseases related to Breast and/or ovarian cancer
- Hereditary breast ovarian cancer syndrome, also linked to BARD1, BRIP1, CDH1, CHEK2 and 7 more
- Gastric cancer, also linked to BARD1, BRIP1, CHEK2, MLH1 and 5 more
- Ovarian cancer, also linked to BARD1, BRIP1, CDH1, MLH1 and 4 more
- Hereditary breast cancer, also linked to BARD1, BRIP1, CDH1, CHEK2 and 2 more
- Lynch syndrome, also linked to CHEK2, MLH1, MSH2, MSH6 and 1 more
- Colorectal cancer, also linked to CHEK2, MLH1, MSH2, MSH6 and 1 more
- Endometrial carcinoma, also linked to CDH1, MLH1, MSH2, MSH6 and 1 more
- Colon carcinoma, also linked to MLH1, MSH2, MSH6 and PMS2
- Mismatch repair cancer syndrome, also linked to MLH1, MSH2, MSH6 and PMS2
- Familial ovarian cancer, also linked to BRIP1, RAD51C and RAD51D
- Li-Fraumeni syndrome, also linked to CHEK2 and TP53
- Fanconi anemia complementation, also linked to BRIP1 and RAD51C
Frequently asked questions
Which genes have records linked to Breast and/or ovarian cancer?
This view contains 12 analyzed proteins: TP53, CHEK2, RAD51D, PMS2, BARD1 and 7 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 5 pathogenic or likely pathogenic variants, 73 variants of uncertain significance and 101 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 187 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center